Allogene Therapeutics, Inc. (ALLO) intrinsic value & 10-year financials
Allogene Therapeutics, Inc. (ALLO) has a Graham intrinsic value of $131.28 per share. At $1.31 on Oct 17, 2026, the stock trades 99% below that value. Over the last 9 fiscal years revenue shrank 91.7% a year to $0, with an average return on invested capital of -42.7%.
- Graham intrinsic value
- $131.28
- Share price (Oct 17, 2026)
- $1.31
- Price vs Graham value
- 99% below
- Market cap
- $289.0M
- Revenue (FY2025)
- $0
- Revenue growth (9-yr CAGR)
- -91.7%
- ROIC (10-yr avg)
- -42.7%
- Free cash flow (FY2025)
- -$149.6M
ALLO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$190.9M | -$0.87 | -$149.6M | — | -56.1% |
| FY2024 | $22.0K | -$257.6M | -$1.32 | -$201.0M | -1241813.6% | -57.7% |
| FY2023 | $95.0K | -$1.6B | -$2.09 | -$239.2M | -344986.3% | -53.9% |
| FY2022 | $243.0K | -$1.2B | -$2.32 | -$225.7M | -138044.9% | -44.4% |
| FY2021 | $38.5M | -$903.3M | -$1.89 | -$206.3M | -664.6% | -29.1% |
| FY2020 | $0 | -$646.3M | -$2.08 | -$181.1M | — | -35.6% |
| FY2019 | $0 | -$396.1M | -$1.83 | -$188.1M | — | -35.1% |
| FY2018 | — | -$211.5M | — | -$47.9M | — | -29.9% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Allogene Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Allogene Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.7% ROIC.
Allogene Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Allogene Therapeutics, Inc. is modeled at -91.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $131.28 per share.